Salarius regains Nasdaq bid price compliance

Salarius Pharmaceuticals, Inc. reports that Nasdaq has notified the company it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. reports that Nasdaq has notified the company it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). To meet this rule, Salarius’ common stock was required to maintain a closing bid price of at least $1.00 per share for 10 consecutive business days.

Nasdaq has placed Salarius under a one-year Mandatory Panel Monitor starting on September 4, 2025, during which any new bid price violation could trigger a delisting determination and another hearing process. The company remains out of compliance with Nasdaq Listing Rule 5550(b)(1), the equity standard, and has until October 20, 2025 to regain compliance with that requirement.

Insights

Equity Market Structure Analyst

Salarius regains bid rule compliance but still faces equity standard hurdle.

Salarius Pharmaceuticals has cleared an important near-term risk by regaining compliance with Nasdaq’s minimum bid price rule, which required its shares to close at or above $1.00 for 10 straight business days. This removes an immediate delisting trigger tied specifically to share price.

However, Nasdaq has imposed a one-year Mandatory Panel Monitor from September 4, 2025, meaning any renewed bid price violation could quickly lead to a delisting determination and another hearing. At the same time, the company remains noncompliant with Nasdaq Listing Rule 5550(b)(1), the equity standard, and has only until October 20, 2025 to resolve that separate listing deficiency.

The combination of monitoring and an equity-standard deadline keeps listing risk present even after the bid price issue was addressed. Subsequent disclosures will show whether Salarius meets the equity standard by the October 20, 2025 timeframe set by the Hearings Panel.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Salarius Pharmaceuticals (SLRX) announce in this 8-K?

Salarius announced that Nasdaq’s Hearings Panel notified the company it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

How did Salarius (SLRX) regain compliance with Nasdaqs bid price rule?

To regain compliance with the Bid Price Rule, Salarius common stock had to maintain a closing bid price of at least $1.00 per share for 10 consecutive business days.

Is Salarius Pharmaceuticals still at risk of Nasdaq delisting?

Yes. Nasdaq placed Salarius under a one-year Mandatory Panel Monitor from September 4, 2025, and a new bid price violation during this period could lead to a delisting determination and another hearing.

Which Nasdaq listing rule is Salarius Pharmaceuticals (SLRX) still not meeting?

Salarius remains noncompliant with Nasdaq Listing Rule 5550(b)(1), known as the equity standard.

What deadline does Salarius have to meet Nasdaqs equity standard?

The company has until October 20, 2025 to achieve compliance with the equity standard, as provided by the Hearings Panels extension.

Did Salarius issue a press release about regaining bid price compliance?

Yes. Salarius issued a press release on September 9, 2025 announcing that it had regained compliance with the Bid Price Rule, which is filed as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 08:04 AM Learn about SEC filing dates

0001615219FALSE2450 Holcombe Blvd.Suite XHoustonTX00016152192025-08-152025-08-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 8.01. Other Events

On September 4, 2025, Salarius Pharmaceuticals, Inc. (“Salarius”) received a letter from the Nasdaq Hearings Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying Salarius that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), as required by the Hearings Panel. To regain compliance with the Bid Price Rule, Salarius’ common stock was required to maintain a closing bid price of $1.00 per share or more for at least 10 consecutive business days.

Nasdaq further notified Salarius that it will be subject to a Mandatory Panel Monitor for a period of one year from September 4, 2025. If, within that one-year monitoring period, the Listing Qualifications Staff finds Salarius out of compliance with the Bid Price Rule that was the subject of the exception, the Staff will issue a delisting determination letter and Salarius will have the opportunity to request a hearing with the Hearings Panel.

The letter notes that Salarius remains noncompliant with Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”) and has until October 20, 2025 to achieve compliance with the Equity Standard per the Hearings Panel’s previously announced granting of Salarius’ extension request.

On September 9, 2025, Salarius issued a press release announcing that that it had regained compliance with the Bid Price Rule. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release of Salarius Pharmaceuticals, Inc., dated September 9, 2025

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: September 9, 2025

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer